Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma

This study is a prospective, single-arm, phase Ⅱtrial. The subjects are patients resectable centrally-located hepatocellular carcinoma in BCLC stage B who are admitted to the Hepatobiliary Surgery Department of Tongji Hospital , Tongji Medical College, Huazhong University of Science and Technology, are over 18 years old, and have signed the informed consent form to voluntarily participate in this study. Through the neoadjuvant treatment of Apatinib mesylate and Camrelizumab combined with TACE before liver resection, it is expected to reduce the tumor size, lower the tumor burden, increase the

Trial Details

NCT ID
NCT07154082
Phase
PHASE2
Sponsor
Wei Zhang
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • TACE (transarterial chemoembolization) combined with targeted/immunotherapy
Locations (sample)
  • Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

  • 1\) Diagnosed with hepatocellular carcinoma by pathological or histological examination.
  • 2\) the patient do not receive any anti-tumor treatment, including but not limited to surgery, radiotherapy, chemotherapy, immunotherapy and target…
  • resectable centrally-located hepatocellular carcinoma in BCLC stage B; Surgical resection was feasible after MDT discussion.
  • 4\) aged 18 to 70 years old, male or female

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →